Liettua - liettua - SMCA (Valstybinė vaistų kontrolės tarnyba)

santen oy - tafluprostas/timololis - akių lašai (tirpalas) - 15 µg/5 mg/ml - timolol, combinations

Euroopan unioni - liettua - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcinos - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.

Euroopan unioni - liettua - EMA (European Medicines Agency)

aimmune therapeutics ireland limited - defatted powder of arachis hypogaea l., semen (peanuts) - peanut hypersensitivity - allergens - palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. palforzia may be continued in patients 18 years of age and older. palforzia should be used in conjunction with a peanut-avoidant diet.

Euroopan unioni - liettua - EMA (European Medicines Agency)

biomarin international limited - vosoritide - achondroplasia - narkotikai kaulų ligų gydymui - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

Liettua - liettua - SMCA (Valstybinė vaistų kontrolės tarnyba)

exeltis baltics, uab - doksilamino-vandenilio sukcinatas/piridoksino hidrochloridas - skrandyje neirios tabletės - 10 mg/10 mg - doxylamine, combinations

Liettua - liettua - SMCA (Valstybinė vaistų kontrolės tarnyba)

exeltis baltics, uab - doksilamino-vandenilio sukcinatas/piridoksino hidrochloridas - modifikuoto atpalaidavimo tabletės - 20 mg/20 mg - doxylamine, combinations

Liettua - liettua - SMCA (Valstybinė vaistų kontrolės tarnyba)

maxpharma baltija, uab - bozentanas - plėvele dengtos tabletės - 125 mg - bosentan

Liettua - liettua - SMCA (Valstybinė vaistų kontrolės tarnyba)

maxpharma baltija, uab - bozentanas - plėvele dengtos tabletės - 62,5 mg - bosentan

Euroopan unioni - liettua - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - aripiprazolas - Šizofrenija - psicholeptikai - Šizofrenijos palaikomuoju gydymu suaugusiems pacientams, stabilizuotam su geriamuoju aripiprazolu.

Euroopan unioni - liettua - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. (miol) - febuksostatas - podagra - antigout preparatai - 80 mg stiprumas:gydymas, lėtinių hyperuricaemia sąlygomis, kai urate nusodinimo jau įvyko (įskaitant istorija, arba buvimas, tophus ir (arba) podagros, artrito). adenuric yra nurodyta suaugusieji. 120 mg stiprumas:adenuric fluorouracilu ir folino lėtinių hyperuricaemia sąlygomis, kai urate nusodinimo jau įvyko (įskaitant istorija, arba buvimas, tophus ir (arba) podagros, artrito). adenuric yra nurodyta prevencijos ir gydymo hyperuricaemia suaugusiųjų pacientams, kuriems atliekama chemoterapija haematologic piktybinių navikų tarpinis aukštos rizikos naviko lizės sindromas (tls). adenuric yra nurodyta suaugusieji.